SLEURO TODAY

Home / Science & Publications

Stopping versus continuing maintenance immunosuppressive therapy in lupus nephritis at 2-3 years

Comment on: “Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial” (Ann Rheum Dis. 2022 Jun 20; doi: 10.1136/annrheumdis-2022-222435) Commented by: Maria G. Tektonidou, Professor of Rheumatology, First Department of Propaedeutic Internal Medicine, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Greece Lupus nephritis (LN) is … Read more

Lack of efficacy of ustekinumab in a phase 3 randomised controlled trial in patients with systemic lupus erythematosus

Comment on: “Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus” (Ann Rheum Dis. 2022; doi: 10.1136/ard-2022-222858) Commented by: Maria G. Tektonidou, Professor of Rheumatology, First Department of Propaedeutic Internal Medicine, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Greece Patients with systemic … Read more

Comment on: Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

Comment on Werth et al., N Engl J Med 2022;387:321-31. DOI: 10.1056/NEJMoa2118024 Comment by Elisabet Svenungsson In clinical practice it is often a challenge to treat cutaneous lupus erythematosus (CLE), especially the discoid and chronic lesions are commonly very resistant to treatment. These lesions cause irreversible damage, which has great impact on the quality of … Read more

Hypomethylation of miR-17-92 cluster in lupus T cells and no significant role of genetic factors in the lupus-associated DNA methylation signature

Comment on: Coit, et al., Ann Rheum Dis 16 June 2022. doi:10.1136/annrheumdis-2022-222656 Comment by: Marta E. Alarcón-Riquelme Epigenetics, and particular the study of the methylation of the CpG nucleotides in DNA has shown that lupus CD4+ T cells have aberrant methylation patterns1 and are poised towards activation of interferon-regulated genes2. DNA methylation is an important … Read more

Combined genetic deficiencies of the classical complement pathway are strongly associated with both systemic lupus erythematosus and primary Sjögren´s syndrome

Comment on: Lundtoft, et al., Arthritis Rheumatol, June 21 2022 (Accepted) DOI: 10.1002/art.42270 Comment by: Marta E. Alarcón-Riquelme Since long ago, we are aware that complement deficiencies are related with the appearance of SLE, particularly in the youth. However, we are not completely aware of the role of complement deficiencies in relation to the risk … Read more

SLEuro today commented articles

Title: Towards a standardization of the Physican Global Assessment (PGA) in Lupus? Comment on: Piga et al. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. The Lancet Rheumatology 2022 Volume 4, Issue 6, Pages e441-e449. https://doi.org/10.1016/S2665-9913(22)00107-2 Commented by: Professor Laurent ARNAUD, Department of Rheumatology, French National Reference Center RESO for … Read more

Quality indicators for systemic lupus erythematosus

Comment on: Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. Commented by: Angela Tincani, Rheumatology and Clinical Immunology Unit, ASST-Spedali Civili and University of Brescia, Italy Systemic lupus erythematosus (SLE) is a very complex disease and in the last 20 years … Read more

Delineating the clinical value of MMF for joint manifestations

Comment on: Five-years drug survival of mycophenolate mofetil therapy in patients with systemic lupus erythematosus: comparison between renal and non-renal involvement. Joint Bone Spine 2021 Jun 22;105246. doi: 10.1016/j.jbspin.2021.105246. Online ahead of print Commented by: Thomas Dörner, Department of Medicine/Rheumatology and Clinical Immunology; Charite Universitätsmedizin Berlin, Germany While MMF has not been approved for SLE, … Read more

Effectiveness of mycophenolate/voclosporin combination therapy in lupus nephritis

Comment on: “Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial” (Lancet. 2021; doi: 10.1016/S0140-6736(21)00578-X.) Commented by: George Bertsias, Rheumatology Clinic, University of Crete School of Medicine, Greece Despite advances in the management of lupus nephritis, still a sizeable number of patients will fail … Read more

A gene-centric pathway stratification of SLE patients

Comment on: “Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing” (Ann Rheum Dis. 2021; 80(1):109-117. doi: 10.1136/annrheumdis-2020-218636) Commented by: George Bertsias, Rheumatology Clinic, University of Crete School of Medicine, Greece SLE is characterized by remarkable clinical and immunological heterogeneity, which likely reflects the variety and complexity of the underlying molecular … Read more